Daily Stock List
FullCircle Registry, Inc. (FLCR)
Today we are highlighting FullCircle Registry, Inc. (FLCR), here at the QualityStocks Daily Newsletter.
FullCircle Registry, Inc. is an acquisition company that provides exit plans to successful profitable businesses in expanding business sectors. The Company’s mission is to provide a home for those who have developed successful companies and have no exit capabilities. FullCircle Registry has opened up subsidiaries to be homes for the Company’s acquisitions. The Company’s shares trade on the OTC Markets’ OTCQB. FullCircle Registry has its head office in Shelbyville, Kentucky.
The Company’s focus is to provide exit capabilities for small to medium sized private, profitable companies via acquisition, to improve its stockholder value while leaving those companies independent where possible to continue to be managed by the team that founded them, and then providing liquidity and greater returns for the founder(s).
Companies that FullCircle Registry owns include FullCircle Entertainment, Inc. and FullCircle Medical Supplies, Inc. Regarding FullCircle Entertainment, the Company purchased Georgetown 14 Cinemas in 2010. It operates in Indianapolis, Indiana. Regarding FullCircle Medical Supplies, the Company is in the process of acquiring a number of DME businesses to provide full state coverage for Louisiana.
Yesterday, FullCircle Registry announced that its S-1 Registration Statement filed with the Securities and Exchange Commission (SEC) became effective, securing a $1.5M financing commitment from Kodiak Capital Group, LLC. Kodiak is an institutional investor based in Newport Beach, California. The funding will provide working capital for operations, to develop the DME infrastructure, acquire DME businesses, and to retire some of FullCircle Registry’s debt, as defined in the Registration Statement.
FullCircle Registry Chief Executive Officer, Mr. Norman L. Frohreich, said, "I am very pleased to have this facility in place as it offers FullCircle access to additional funds that may be required for working capital and to begin the acquisition of Durable Medical Equipment businesses (DMEs) in Louisiana and South Carolina. FullCircle has been searching for funding to proceed with its acquisition business model for some time. Over the last year FullCircle has issued Letters of Intent to purchase several medical supply businesses, using stock, notes and cash. The negotiations involving these acquisitions are contingent on securing capital.”
FullCircle Registry, Inc. (FLCR), closed Friday's trading session at $0.023, down 34.29%, on 266,200 volume with 14 trades. The average volume for the last 60 days is 33,108 and the stock's 52-week low/high is $0.012/$0.07.
Coates International Ltd. (COTE)
SmallCapVoice, Wallstreetlivechat, OTCPicks, FeedBlitz, and AllPennyStocks reported earlier on Coates International Ltd. (COTE), and we report on the Company also, here at the QualityStocks Daily Newsletter.
Wall Township, New Jersey headquartered Coates International Ltd. is a precision engineering company. It specializes in the development of technologies that advance the standard combustion engine with the goals of significantly improving fuel efficiency and power generation, and lessening harmful emissions and long-term maintenance costs. The Company engages in the development of the Coates Spherical Rotary Valve (CSRV) System. The CSRV system technology is used in piston-driven internal combustion engines. Coates International lists on the OTC Markets’ OTCQB.
The CSRV system technology is used in wide-ranging applications. These include engines for electric power generators for home use, industrial complexes, and grid installations; and engines to power motorcycles, automobiles, light trucks, heavy trucks, machinery, railroads, marine engines, military equipment, light aircraft, helicopters, lawn mowers, snowmobiles, jet skis, and more.
The CSRV contains two spherical rotary valves assembled on two separate shafts. One is for inlet and one is for exhaust. They rotate on ceramic carbon bearing with no oil lubrication. The design of the CSRV system technology is to replace the intake and exhaust conventional poppet valves used in piston-driven stationary, automotive, motorcycle, and marine engines.
The spheres do not make contact with any part of the housing. The seals are a floating type and consist of a ceramic material. They have two piston rings and are floating in a small cylinder-type chamber. They are activated by the compression and the combustion strokes of the engine. This allows 100 percent sealing effectiveness, upon compression.
Coates International is now established in China for the manufacturing of the Coates CSRV Engines and Industrial Generators. Coates Power, Inc. Ltd. and two other Chinese companies have joined up with Coates Power to mass produce the Coates CSRV® products.
In November, Coates International announced that the Coates Industrial CSRV Natural Gas Electric Power Generator arrived in China to go to the Coates Power Inc., Ltd. industrial plant. The Coates Industrial CSRV Natural Gas Electric Power Generator was transported over road to Coates Power Inc. at Xianning City, Hubei Province, China.
Coates International Ltd. (COTE), closed Friday's trading session at $0.013, up 3.17%, on 4,540,951 volume with 108 trades. The average volume for the last 60 days is 733,672 and the stock's 52-week low/high is $0.008/$0.06.
AtheroNova, Inc. (AHRO)
Streetwise Reports, RedChip, FeedBlitz, and UltimatePennyStock reported earlier on AtheroNova, Inc. (AHRO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
AtheroNova, Inc. is a biotechnology company that lists on the OTCQB. The Company’s focus is on the discovery, research, development, and licensing of novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans. AtheroNova’s plan is to develop - along with its lead compound AHRO-001 - multiple applications for its patented and patents-pending therapies in markets that include Cardiovascular Disease, Stroke, and Peripheral Artery Disease. All of these have been linked to atherosclerosis. AtheroNova is based in Irvine, California.
AHRO-001 is the Company’s first novel application for the treatment and prevention of atherosclerosis. AHRO-001 has shown positive results in animal models for regression of plaque. It is undergoing human studies in pursuit of these same successful results.
The AHRO delipidization process came about by co-inventors Dr. Giorgio Zadini and Dr. Filiberto Zadini. Their research is covered by AHRO patent applications. The AHRO delipidization process dissolves plaques in artery walls so they are removed through normal body processes. AHRO-001 penetrates through the atherosclerotic fibrous cap and, through delipidization, causes quick reduction in the size of the deposits of soft vulnerable plaque in an artery's walls.
AtheroNova is developing AHRO-001 to directly compete with statins that largely lower cholesterol and stabilize plaque. AHRO-001, in preclinical studies, did not show adverse effects. AHRO-001 was also well tolerated at high doses. Concerning pre-clinical studies, AtheroNova successfully completed preclinical studies at UCLA and Cedars‐Sinai. In these studies, use of AHRO-001 led to a 95 percent reduction in innominate arterial plaque formation versus the control group.
AtheroNova announced, in December 2013, achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study goal is to evaluate the safety, tolerability, and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is taking place in Russia with AtheroNova's licensing partner, OOO CardioNova.
AtheroNova announced this past July that its partner, CardioNova, accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. The Phase 1b trial will be a continuation of the AHRO-001 Phase 1 safety trial completed in February 2014, in which patients were dosed with AHRO-001 for up to three weeks. AtheroNova will remain blinded to data from the earlier Phase 1 cohorts until the completion of Phase 1b. At that time the topline data will be presented together in approximately 6 to 8 months.
AtheroNova, Inc. (AHRO), closed Friday's trading session at $0.24, down 17.21%, on 21,990 volume with 14 trades. The average volume for the last 60 days is 62,034 and the stock's 52-week low/high is $0.245/$6.70.
Novus Robotics, Inc. (NRBT)
Wallstreetlivechat, OTC Stock Review, and Market Bulls reported previously on Novus Robotics, Inc. (NRBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Novus Robotics, Inc. involves in the engineering, design, and manufacture of robotics and automation technology solutions for tube bending machines. The Company’s wholly-owned subsidiary is D & R Technology, Inc. Through D & R Technology, Novus Robotics will provide state of the art automation technologies through its automated tube bending machines. The Company designs, engineers, and builds these for the automotive industry to solve its customers' complex automation needs, increase efficiencies, as well as improve manufacturing processes.
Novus Robotics has developed partnerships with market leaders. Through these developed partnerships it provides its customers with business consulting; implementation services; integration solutions; design collaboration; and complementary products essential for successful deployment of its solutions. The Company’s principal focus is on product engineering and manufacturing processes to ensure the highest quality, product features and efficient manufacturing processing.
Novus Robotics is a full service provider of turn-key production solutions, specializing in tubular components for its tube bending machines. Its expertise is in the areas of automation and machinery for computer numerical control (CNC) bending, forming, piercing, and laser cutting. The Company produces spare parts for the manufacturing equipment it designs. However, Novus does not produce spare parts for automobiles.
The Company’s D & R Technology subsidiary also makes custom-built tooling, provides process development, production support, continuing service, preventive maintenance and more. D & R is emerging as one of the globe’s top providers of automated manufacturing solutions, used by three of the top ten automotive part suppliers internationally. D&R Technology is applying its service solutions to other markets, including medical robotics, personal robotic devices, as well as the water treatment industry.
Novus Robotics’ principal activities to date include designing and the installation of retrofits to existing automated systems, automated spare parts for its tube bending machines, automated maintenance, and repairs. The Company is presently offering products including Seat Frame Systems, IP Tube systems, and Integrated Bend-Weld Systems for the automotive industry.
The Company will provide automation solutions to a broad assortment of customers and industries. These range from large Fortune 500 companies to small privately-held businesses. Novus Robotics’ automated solutions can be found in manufacturing, assembly and processing lines throughout the U.S., Canada, Mexico and South America.
Novus Robotics, Inc. (NRBT), closed Friday's trading session at $0.125, up 13.64%, on 415,078 volume with 60 trades. The average volume for the last 60 days is 91,418 and the stock's 52-week low/high is $0.027/$0.34.
MRI Interventions, Inc. (MRIC)
Wall Street Resources, Real Pennies, and FeedBlitz reported earlier on MRI Interventions, Inc. (MRIC), and we choose to highlight the Company today, here at the QualityStocks Daily Newsletter.
MRI Interventions, Inc. is a medical device company listed on the OTC Bulletin Board. It develops and commercializes distinct platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or MRI, guidance. Using a hospital's existing MRI suite, the design of its FDA-cleared and CE-marked ClearPoint® system is to enable a range of minimally invasive procedures in the brain. ClearPoint® is an integrated system of hardware components, disposable components, and intuitive, menu-driven software.
MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, relating to the ClearPoint® system. In addition, the Company is working with Boston Scientific to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications.
The ClearPoint® system enables real-time MRI-guided navigation for a broad array of minimally-invasive neurosurgery procedures. The platform is especially well-suited for facilitating drug delivery directly to brain tumors. The ClearPoint® system provides MRI-based stereotactic guidance for the placement and operation of instruments or devices during the planning and operation of neurological procedures performed within the MRI suite. ClearPoint® procedures can be used with 1.5T and 3T scanners.
MRI Interventions is also developing the ClearTrace® system in partnership with Siemens Healthcare. This is to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation.
MRI Interventions announced in August 2014 that neurosurgeons at UC San Diego Health System used the ClearPoint® system's platform capabilities to facilitate three same-setting MRI-guided neurosurgical procedures for a single patient. The team, led by Clark C. Chen, MD, PhD, Vice-Chairman of Academic Affairs for the Division of Neurosurgery at UC San Diego School of Medicine, biopsied a patient's brain tumor, aspirated a fluid-filled section of the tumor, and ablated the tumor. This was all under real-time MRI guidance enabled by the ClearPoint® system in the hospital's diagnostic MRI suite.
Today, MRI Interventions announced that it entered into a definitive securities purchase agreement with a group of investors for the private placement of roughly15.8 million shares of its common stock and warrants to purchase approximately 6.3 million shares of its common stock.
Mr. Frank Grillo, President and Chief Executive Officer-elect of MRI Interventions, said, "We are very pleased to secure this financing. The proceeds from the private placement will strengthen our balance sheet, fund our ongoing commercialization efforts for our ClearPoint® Neuro Intervention System, a next generation platform for performing real-time, MRI-guided minimally invasive neurosurgery, and drive the priorities I have established for the company."
MRI Interventions, Inc. (MRIC), closed Friday's trading session at $0.927, up 7.79%, on 222,965 volume with 109 trades. The average volume for the last 60 days is 45,615 and the stock's 52-week low/high is $0.652/$1.58.
AmbiCom Holdings, Inc. (ABHI)
SmallCapVoice, TheOTCInvestor, PennyStocks24, Wallstreetlivechat, Pumps and Dumps, and Nebula Stocks reported earlier on AmbiCom Holdings, Inc. (ABHI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 1997, AmbiCom Holdings, Inc. was a leading designer and developer of advanced wireless products centering on Wi-Fi and Bluetooth® applications for the wireless medical, healthcare, and automotive industries. The Company is now focusing on tuning software products, optimizing complex Information Technology (IT) environments, servers, and personal computers. AmbiCom Holdings has its corporate headquarters in Milpitas, California. The Company’s shares trade on the OTC Markets’ OTCQB.
Additionally, AmbiCom is a distributor of unique healthcare products. The Company designs and develops wireless home medical devices for non-health care applications for the retail market. This includes solar ionic toothbrushes (Soladey Ionic Toothbrush J3X) that in general use light to activate an ionic process to remove plaque.
AmbiCom Holdings announced in February of this year that it entered into a Letter of Intent (LOI) for an Asset Purchase Agreement with Veloxum Corp. Veloxum is a performance management company that specializes in optimizing complex Information Technology (IT) environments. On May 14, 2014, AmbiCom Holdings announced that it reached closing the Asset Purchase Agreement with Veloxum.
Veloxum was established with the aim to apply active and continuous optimization to manage complex IT environments for optimum performance. The Veloxum team covers the disciplines of networking, servers, applications, operating systems and high speed data transfer.
Earlier this month, AmbiCom announced that it entered into a non-exclusive relationship with Greater Intell. With this relationship, AmbiCom’s Veloxum optimization solution will sell under the giOptimum brand. Powered by Veloxum, giOptimum automatically evaluates and adjusts server and workstation settings to improve performance and capacity of existing systems.
AmbiCom earlier created the brand Lagranger to represent the Veloxum gaming optimization for the huge gaming marketplace through enterprise server and home personal computer (PC) solutions to enhance performance for improved gaming-play and user experience.
This week, AmbiCom Holdings announced that it completed 150,000 successful trial installations of Veloxum solution software products targeting home users. Veloxum actively and continuously optimizes physical and virtual computers through optimizing operating system and application settings. This milestone will give AmbiCom Holdings access to the worldwide installed base of 2.3 billion* Personal Computers (*Gartner Research).
AmbiCom Holdings, Inc. (ABHI), closed Friday's trading session at $0.187, down 10.95%, on 118,238 volume with 29 trades. The average volume for the last 60 days is 48,929 and the stock's 52-week low/high is $0.102/$0.60.
Integrated BioPharma, Inc. (INBP)
Zacks, The Stock Psycho, StockMister, OTCPicks, HotShotStocks, Top Gun, and AllPennyStocks reported on Integrated BioPharma, Inc. (INBP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed Integrated BioPharma, Inc. engages chiefly in the manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Its customers are located mainly in the U.S., Luxembourg and Canada. Founded in 1979, Integrated BioPharma was previously known as Integrated Health Technologies, Inc. The Company has its corporate headquarters in Hillside, New Jersey.
Integrated BioPharma develops, manufactures, and distributes, around the world, more than 130 products. It does so through several wholly-owned subsidiaries. Its companies include AgroLabs, Inc., Chem International, IHT Health Products, Inc., Manhattan Drug Company, and Vitamin Factory. Integrated BioPharma operates through three segments. These are Contract Manufacturing, Branded Proprietary Products, as well as Other Nutraceutical Businesses.
AgroLabs manufactures and markets healthful nutritional products under the Naturally Noni, Naturally Pomegranate, Naturally Aloe, and Naturally Mangosteen brands. AgroLabs also distributes globally in Canada, Germany, Japan, Korea, Mexico, Taiwan and the United Kingdom (UK). Integrated BioPharma’s Chem International offers a broad spectrum of Roche Vitamins' food and cosmetic products.
Integrated BioPharma’s IHT Health Products sells and distributes fine chemicals. These include science-based proprietary products and value added formulations. It sells and distributes these to the nutritional, pharmaceutical, food, as well as cosmetic industries.
IHT products include vitamins, amino acids, herbal extracts, Over-the-Counter (OTC) pharmaceuticals, excipients, and unique patented products. IHT Health Products has established strategic marketing alliances with different research based companies, which have developed patented products unique to the industry.
Moreover, the Company’s Manhattan Drug Company provides vitamins and nutritional formulations. It engages in the manufacturing of tablets, capsules, or blends; packaging and labeling in bulk; help in product registration internationally, and distribution of finished product. Manhattan also engages in analytical and microbiological testing by way of its in-house laboratories.
Furthermore, Integrated BioPharma’s Vitamin Factory sells nutritional supplements directly to the consumer via mail order catalogs and over the Internet. Its product categories are dietary supplements, liquid items, sports supplements, and skincare supplements.
Integrated BioPharma, Inc. (INBP), closed Friday's trading session at $0.09, up 5.63%, on 49,900 volume with 4 trades. The average volume for the last 60 days is 62,623 and the stock's 52-week low/high is $0.08/$0.34.
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.30, up 42.86%, on 3,353 volume with 5 trades. The stock’s average daily volume over the past 60 days is 1,290 and its 52-week low/high is $0.06/$0.60.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
Dominovas Energy Corp. Appoints International Business Professional to Board of Directors
Dominovas Energy and Delphi Sign MOU
Nhale, Inc. (NHLE)
The QualityStocks Daily Newsletter would like to spotlight Nhale, Inc. (NHLE). Today, Nhale, Inc. closed trading at $0.33, up 26.92%, on 129,680 volume with 52 trades. The stock’s average daily volume over the past 60 days is 57,987, and its 52-week low/high is $0.14/$1.33.
Nhale, Inc. (NHLE) develops and sells leading-edge technology in alignment with its mission to become a recognized, premier innovator in cannabis cultivation, dispensaries, testing and scientific products. Nhale explores innovations that will position the company on the front lines of the marijuana revolution.
Nhale is currently aggressively focused on grow operations in states where cannabis is legal, or soon to be legal, such as Oregon, Alaska and Florida. As an increasing number of states move towards legalization for medical or recreational use, growers are positioned to benefit from economies of scale due to escalating demand. Focusing on candidates in the cultivation space, Nhale is poised grow into a successful, sustainable enterprise through product or company acquisition in this explosive space.
Growpod, Nhale’s self-contained grow environment technology, is one of the company’s products and an entry point into the promising cultivation technology space. Growpod uses “controlled environment agriculture” to optimize plant development, plant quality and production efficiency in all climates and seasons.
Nhale believes innovation produces profitability, especially in growth-stage organizations entering emerging industries. This belief guides Nhale’s strong commitment to develop and commercialize cutting-edge consumer-oriented products primed for rapid commercialization. The company has identified strategic industry partnerships to support this growth objective and to secure an increasing footprint in the booming marijuana market. Disclaimer
Nhale, Inc. Company Blog
Nhale, Inc. News:
Nhale (NHLE) Receives $10 Million Commitment to Complete Acquisitions
Nhale (NHLE) Forecasts Revenues of More Than $30 Million in 2015 From Deals Under Consideration & Receives $10 Million Commitment to Complete Acquisitions
Recreational Pot Sales Posting Solid Gains as Nhale (NHLE) and Washington Grower Proceed With Negotiations
Ecrypt Technologies, Inc. (ECRY)
The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.127, up 7.63%, on 557,261 volume with 142 trades. The stock’s average daily volume over the past 60 days is 2,111,700 and its 52-week low/high is $0.09/$0.59.
Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.
Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.
The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.
Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer
Ecrypt Technologies, Inc. Blog
Ecrypt Technologies, Inc. News:
Ecrypt Technologies Update Regarding Promotional Activity on Its Stock
Ecrypt CEO Appointed to ProCM's Independent Training and Certification Board of Directors
Microsoft CSO and Ecrypt CEO Share Inaugural Security Industry Award
Pan Global Corp. (PGLO)
The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.0109, up 6.86%, on 15,650 volume with 9 trades. The stock’s average daily volume over the past 60 days is 86,948, and its 52-week low/high is $0.005/$0.359.
Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.
The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.
Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.
Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer
Pan Global Corp. Company Blog
Pan Global Corp. News:
Pan Global, Corp. Comments on Industry Report That the India Renewable Energy Market Opportunity Is Worth USD $10.5 Billion by 2017
Pan Global, Corp. Shareholder Update: Small-Hydro Plant Connected to Power Grid in Northern India
Pan Global, Corp. Increases Equity Stake in 5.7 MW Small-Hydro Plant in Northern India
Well Power Inc. (WPWR)
The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.0414, up 6.15%, on 153,574 volume with 26 trades. The stock’s average daily volume over the past 60 days is 114,258, and its 52-week low/high is $0.03/$2.00.
Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.
The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.
Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.
Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer
Well Power Inc. Company Blog
Well Power Inc. News:
Well Power - Letter from President to Shareholders
Well Power Inc. to host second webinar on proprietory micro-refinery technology
Well Power Inc. Information to be Available through S&P Capital IQ Corporation Records Program
WRIT Media Group, Inc. (WRIT)
The QualityStocks Daily Newsletter would like to spotlight WRIT Media Group, Inc. (WRIT). Today, WRIT Media Group, Inc. closed trading at $0.0067, up 3.08%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 57,375, and its 52-week low/high is $0.0065/$0.50.
WRIT Media Group, Inc. (WRIT) is focused on expanding in the digital media industry. The holding company currently operates under two different divisions: content creation via Front Row Networks, and "retro" video gaming via Retro Infinity Inc. and Amiga Games Inc.
The company’s Front Row Networks subsidiary produces, acquires and distributes live concerts in 2D and 3D format for initial worldwide digital broadcast into digitally-enabled movie theaters. In addition to presenting live concerts to massive audiences at lower ticket prices, Front Row Networks will license the content for many different distribution channels and sell merchandize where the live concerts are exhibited. The subsidiary also secures and distributes non-concert alternative theatrical programming and aims to acquire the broadest range of rights for exclusive programming.
Retro Infinity specializes in licensing classic computer and console video game libraries and adapts and republishes the most popular titles for smartphones, modern game consoles, micro-consoles, PCs, and tablets. The company leverages platform and classic game brands, coupled with proprietary technologies, to create new revenue from dormant game libraries.
Amiga Games Inc. shares resources with Retro Infinity to adapt and republish the most popular titles from the Amiga family of computers for smartphones, modern game consoles, micro-consoles, PCs, and tablets. WRIT Media Group leverages the Amiga brand along with game brands of the past and proprietary technologies to create new revenue from classic games that have proven their ability to sell very well.
Together with its subsidiaries, WRIT Media Group is well positioned to benefit from the market growth and increased demand for alternative theatrical, mobile, and interactive content. Disclaimer
WRIT Media Group, Inc. Company Blog
WRIT Media Group, Inc. News:
WRIT Media Group Announces Product Updates and NASCAR Event Recap
Retro Infinity Sponsors NASCAR Driver Carlos Contreras' Record-Breaking 99th Career Race
WRIT Media Group (WRIT) CEO Featured in Exclusive QualityStocks Interview
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.2886, up 3.08%, on 13,841 volume with 8 trades. The stock’s average daily volume over the past 60 days is 167,208, and its 52-week low/high is $0.15/$1.00.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial
Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible
Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Boreal Water Collection, Inc. (BRWC) to Exhibit at China's Largest Food Show
- Cannabics Pharmaceuticals, Inc. (CNBX) engages with Mountain High Products in Colorado
- Cleartronic, Inc. (CLRI) Announces Capitalization Benefit Plan and Expansion of Board of Directors
- Coastal Integrated Services, Inc. (COLV) Announces Engagement of QualityStocks Investor Relations Services
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
- Ecrypt Technologies, Inc. (ECRY) Update Regarding Promotional Activity on Its Stock
- Falcon Crest Energy (FCEN) Names Michael Cvetanovic to Advisory Council
- IFAN Financial, Inc. (IFAN) Reaches Technology Development Milestones, Receives Approval From Apple and Google
- Intercept Energy Services, Inc. (IESCF) Reports Third Quarter 2014 Results and Engages Investor Relations Firm
- Mobile Lads Corp. (MOBO) Acquires Innovative Online Coupon Platform, CouBox
- Nhale, Inc. (NHLE) Receives $10 Million Commitment to Complete Acquisitions
- One World Holdings, Inc. (OWOO) Prettie Girls! Dolls Make National TV Debut on Popular Fox Daytime Talk Show, "The Real"
- Pan Global Corp. (PGLO) Comments on Industry Report That the India Renewable Energy Market Opportunity Is Worth USD $10.5 Billion by 2017
- Pure Hospitality Solutions, Inc. (PNOW) Announces Retooled Booking Software: 2015 Launch, Slated to Be Industry Regional Leader
- Sibling Group Holdings, Inc. (SIBE) Interviewed by TheStockRadio.com
- Technology Applications International, Inc. (NUUU) Rejuvel Int'l, Inc. Will Have its Products Included in Celebrity Gift Bags at the 15th Annual Latin GRAMMY® Awards Show at the MGM Grand in Las Vegas
- VistaGen Therapeutics, Inc. (VSTA) Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) to host second webinar on proprietory micro-refinery technology
- WordLogic Corp. (WLGC) Inks Deal to Monetize Intellectual Property for General Electric (GE)
- WRIT Media Group, Inc. (WRIT) Announces Product Updates and NASCAR Event Recap
- Zenosense, Inc. (ZENO) Hospital Collaboration - 400 Person Lung Cancer Detection Trial